The Children's Hospital Corporation, doing business as Boston Children's Hospital, received a $249,645 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award will fund research to develop advanced genetic engineering techniques to generate tumor-specific B cells that can be used to study their role in tumor progression and potentially lead to new cancer immunotherapy strategies. Specifically, the research aims to redirect the specificity of B cell receptors towards the HER2 tumor antigen, and evaluate the efficacy and safety of this B cell-based adoptive immunotherapy approach in mouse models of breast cancer. The project period runs from January 1, 2025 to December 31, 2026.
Generated 3/4/25, 5:10 AM